Work

Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.2509

Authors: Geoffrey R. Oxnard, Suresh S. Ramalingam, Myung-Ju Ahn, Sang-We Kim, Helena Alexandra Yu, Hideo Saka, Leora Horn, Koichi Goto, Yuichiro Ohe, Mireille Cantarini, Paul Frewer, Michael Lahn, James Chih-Hsin Yang

Institutions: Dana-Farber Cancer Institute, Emory University, Winship Cancer Institute, Samsung Medical Center, Asan Medical Center, University of Ulsan, Memorial Sloan Kettering Cancer Center, Nagoya Medical Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, National Cancer Center Hospital East, AstraZeneca (United Kingdom), National Taiwan University, National Taiwan University Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2921873908

Cites:

Cited by: 46

Related to: 10